Navigation Links
Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
Date:11/2/2007

- Roche progresses R1626 into phase IIb study, called POLI 1 -

BOSTON, Nov. 2 /PRNewswire/ -- R1626, one of Roche's new investigational drugs for chronic hepatitis C virus (HCV) infection, has shown promising antiviral activity when given in combination with PEGASYS(R) (peginterferon alfa-2a) and COPEGUS(TM) (ribavirin), according to results being presented at the American Association for the Study of the Liver Disease (AASLD) meeting, being held in Boston, Nov. 2-6. After four weeks of treatment with this triple combination, the virus could no longer be detected in up to 81 percent of patients, with a mean decrease in viral load of 5.2 log10 from baseline. This is indicative of a robust virological response, and R1626 is being progressed into Phase IIb study as a result of these findings.

R1626 belongs to a class of antivirals called polymerase inhibitors, which are being investigated in combination with the current standard of care, pegylated interferon and ribavirin. The hope is that this combination will increase the number of patients who are able to be successfully treated for hepatitis C.

"The results from this Phase IIa study show that R1626 has a profound antiviral effect when used in combination with PEGASYS plus COPEGUS," said Dr. Paul Pockros, Scripps Clinic, San Diego, California, the lead investigator of the study. "This effect of R1626 in combination therapy, along with the lack of resistance observed to date, means that R1626 could be an exciting drug for patients with hepatitis C, if a safe and acceptable dosing regimen can be determined in future studies."

Antiviral Activity and Safety Results Being Presented at AASLD

The multicenter Phase IIa study enrolled patients with genotype 1 chronic HCV who have not previously received treatment. The objectives were to evaluate the four-week activity and safety of combining R1626 with PEGASYS alone or R1626 with PEGASYS plus COPEGUS in comparison to PEGASYS/COPEGUS,
'/>"/>

SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
5. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
11. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... CLEVELAND , Jan. 14, 2014 NineSigma ... will hold its Innovation Leadership Summit , May ... in Cleveland Ohio . ... innovators and organizations committed to breakthrough achievements through open ...
(Date:1/14/2014)... New York , January 14, 2014 ... Closed System Transfer Devices (CSTD) for hazardous drugs, today announced ... for the fourth straight year.   ... for pharmacy technicians, pharmacists, nurses and other medical ...
(Date:1/14/2014)... Spark Therapeutics , a late-stage gene therapy company, has ... a Phase 3 study for inherited retinal dystrophies caused by mutations ... Marrazzo , is presenting this and other corporate updates today, at ... Francisco . Marrazzo said Spark was able to achieve its ...
Breaking Medicine Technology:Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 4Equashield's Sales Grow by 60% in 2013 2Spark Therapeutics Achieves Recruitment Goal in Phase 3 Gene Therapy Clinical Study for Inherited Blindness 2Spark Therapeutics Achieves Recruitment Goal in Phase 3 Gene Therapy Clinical Study for Inherited Blindness 3
... 9, 2011   Endo Pharmaceuticals (Nasdaq: ENDP ) today ... Conference on Tuesday, March 15, 2011 at 3:45 p.m. ET.  Dr. ... the company,s products and development programs. The presentation will ... www.endo.com under the investors section.   ...
... Accumetrics, Inc., a privately-held developer and marketer ... easy-to-use point-of-care system for measuring platelet reactivity to ... were recently published in The Annals of ... platelet reactivity as a new recommendation for preoperative ...
Cached Medicine Technology:2011 Surgical Guidelines Recommend Point-of-Care Platelet Reactivity Testing Prior to Surgery 22011 Surgical Guidelines Recommend Point-of-Care Platelet Reactivity Testing Prior to Surgery 3
(Date:4/24/2014)... Nancy Chiaravalloti, PhD, of Kessler Foundation was named ... Jersey City, New Jersey. Dr. Chiaravalloti spoke on April ... the topic of "Treating Cognitive Deficits Following Neurological Illness ... be a part of the long legacy of the ... Chiaravalloti. "The field of rehabilitation research is a rewarding ...
(Date:4/24/2014)... scientists a better understanding of drug interactions, which are ... , When two or more medications are taken at ... effectiveness of the other. Similarly, one drug may ... are a major cause of illness and hospitalization. ... scope of drug studies in humans. Limits come ...
(Date:4/24/2014)... N.C. April 24, 2014 ,Take me out ... apple slices and kale chips. The more likely culprits ... Crackerjacks. , Unfortunately for children who play youth ... be contributing to weight problems, according to researchers at ... the current online edition of Childhood Obesity , ...
(Date:4/24/2014)... boring and irrelevant, could offer an alternative to heart ... Milena Furtado, and her team from the Australian Regenerative ... cell fibroblast is a close relative to a cardiomyocyte, ... In research published today in Circulation Research , ... cells due to their genetic program, and will aid ...
(Date:4/24/2014)... give than to receive at least if you,re an ... The study found that 15- and 16-year-olds who find pleasure ... members, are less likely to become depressed than those who ... money for themselves. , The researchers detail their findings in ... , The study focused on the ventral striatum, a brain ...
Breaking Medicine News(10 mins):Health News:Kessler Foundation scientist named 63rd Mendel Lecturer by St. Peter's University 2Health News:Large-scale identification and analysis of suppressive drug interactions 2Health News:Take the bat, leave the candy 2Health News:Boring cells could hold the key to heart disease 2Health News:Study: Altruistic adolescents less likely to become depressed 2
... doing the rounds that global warming in the East ... A novel research by an international team places ... malaria’s spread, along with other factors like drug and ... University of Michigan theoretical ecologist Mercedes Pascual, has contributed ...
... with danger, is also the color of blood, signaling perpetuation ... of blood on a daily basis to cater to patients ... Sunderland have set the ball rolling, campaigning and urging people ... the run-up to Easter. ,Take the case of ...
... suggests that patients on the newer medications for diabetics ... spent between $920 and $1,760 less on annual total ... lead author and the Merrell Dow professor of pharmacy ... of medical records data on patients who took thiazolidinediones ...
... between widely used childhood medicines and the risk of developing ... allergies, expose the kids to pets and dirt early. The ... is known as the hygiene hypothesis. , It ... fields and farm animals, leaves people more susceptible to a ...
... review of several studies conducted on cancer-causing chemicals has ... babies as a consequence of exposure to organochlorines//. Pesticides ... such chemicals and may be passed on to humans ... it can be indirectly passed on to human beings ...
... cancer is one of the deadliest diseases in UK. Symptoms ... a need to rush to the loo//. ,Hence ... to increase awareness about prostate cancer. Prostate cancer kills 220 ... UK. ,Mr Campbell has won the support ...
Cached Medicine News:Health News:New Diabetic Drugs More Effective than Older Ones 2Health News:A Sneak Preview of Human’s Susceptibility to Auto Immune Disease, Allergy, Asthm 2Health News:Parents Concerned About Pesticide And Cancer Risk To Babies 2
... Geometric Data Hemastainer. Formulated to ... quality control tested on human ... staining and absence of precipitate. ... a minimum of eight hours ...
... Unique molecular suspension in methanol ... blood, chromosome, and histology smears. Our ... that rapidly penetrates cellular elements producing ... nuclear detail and unexcelled brilliance in ...
Wright-Giemsa Stain Solutions...
... Stain is ideal for stat, routine or ... smears and bone marrow. Our unique manufacturing ... yield excellent color intensity and morphological differentiation. ... in the Wright's staining procedure and includes ...
Medicine Products: